Naegleria Fowleri: The Emerging Threat to the Human Brain

Authors: Dipiksha Panchal; Mahesh Rawal; Prasang chandaliya; Manjit Singh; Harshvardhan Singh Parmar; kiran Joshi; Gopal Kumawat
DOI
10.5281/zenodo.20367250
DIN
IMJH-OCT-2025-2
Abstract

Naegleria fowleri, the so-called "brain-eating amoeba," is a thermophilic free-living amoeboflagellate protozoan that causes Primary Amoebic Meningoencephalitis (PAM) — one of the deadliest human infectious diseases ever documented, with a case fatality rate exceeding 97%. Despite six decades of scientific investigation since its first characterisation in 1965, PAM remains therapeutically refractory, with fewer than ten globally documented survivors. This comprehensive review synthesises current knowledge across all dimensions of N. fowleri biology and clinical science: its taxonomy within the phylum Percolozoa; the morphology and functional roles of its trophozoite, flagellate, and cyst forms; its thermophilic ecology and widening environmental distribution; global and Indian epidemiology, including the unprecedented 2024–2025 Kerala outbreak; the molecular mechanisms of olfactory nerve invasion and central nervous system destruction; an expanded catalogue of virulence factors (naegleriapores, Nfa1, cysteine proteases, matrix metalloproteinases); the host innate and adaptive immune response; clinical staging from prodrome to coma; and diagnostic strategies encompassing cerebrospinal fluid (CSF) microscopy, culture, polymerase chain reaction (PCR), and neuroimaging. Therapeutic coverage includes the pharmacological profiles of amphotericin B and miltefosine, CDC-recommended combination regimens, the fundamental challenge of blood–brain barrier penetration, and an appraisal of emerging drug candidates (auranofin, nitroxoline, berberine, and nanotechnology-based delivery systems). The review also evaluates prevention strategies at individual, institutional, and governmental levels, including guidelines from the CDC, WHO, and ICMR. The article concludes with a critical assessment of future research priorities: point-of-care diagnostics, climate-integrated surveillance, paediatric pharmacokinetics, and vaccine development. Given the organism's escalating global epidemiological footprint against a backdrop of climate-driven freshwater warming, a deepened scientific and public health engagement with N. fowleri is both timely and imperative.

Keywords
Naegleria fowleri Primary Amoebic Meningoencephalitis (PAM) brain-eating amoeba miltefosine amphotericin B thermophilic protozoa Kerala outbreak blood–brain barrier free-living amoeba
Download Options
Download Full PDF
Share Article
Facebook Twitter LinkedIn
Introduction

Naegleria fowleri occupies a singular position in the landscape of human infectious disease — an organism that is simultaneously omnipresent in natural environments and almost invariably lethal once human infection is established. Colloquially termed the "brain-eating amoeba," this thermophilic free-living amoeboflagellate protozoan is the causative agent of Primary Amoebic Meningoencephalitis (PAM), a fulminant, rapidly progressive infection of the central nervous system (CNS) that advances from prodromal symptoms to fatal brainstem herniation within five to eighteen days. The case fatality rate has persistently exceeded 97% across more than six decades of modern medicine, placing PAM among the most lethal human infections ever characterised.

Within the genus Naegleria — which encompasses over 47 environmentally distributed species — N. fowleri stands uniquely and categorically apart as the single species definitively and consistently established as a human neuropathogen. This biological uniqueness is not incidental; it reflects a specific constellation of pathogenic attributes that converge to produce a degree of virulence unmatched among free-living environmental organisms: thermal tolerance precisely calibrated to mammalian core body temperature, a nasal portal of CNS entry that bypasses systemic immune surveillance, pore-forming cytolytic peptides (naegleriapores) capable of osmotic neuronal destruction, and specialised amoebostome structures enabling the physical extraction of cytoplasm from living neurons through trogocytosis.

The epidemiology of PAM presents a paradox: N. fowleri is cosmopolitan in distribution, isolated from warm freshwater environments across all inhabited continents, yet human infection is extraordinarily rare. This paradox reflects the uniquely demanding transmission requirements — forcible nasal entry of water carrying viable trophozoites to the olfactory mucosa — rather than any limitation in the organism's pathogenic potential. Once this threshold is crossed, the outcome is almost invariably catastrophic. The explosive proliferation of trophozoites within the structurally confined subarachnoid space, combined with concurrent enzymatic and mechanical tissue destruction, produces bilateral haemorrhagic necrotising meningoencephalitis at a speed unmatched by any other commonly encountered human infection.

From a pharmaceutical perspective, PAM encapsulates some of the most intellectually demanding challenges in contemporary clinical pharmacology: CNS drug delivery across the blood–brain barrier (BBB), selectivity challenges arising from the shared eukaryotic cellular architecture of pathogen and host, drug repurposing methodologies applied to an ultra-rare disease, and management of paediatric emergencies under extreme time pressure. These challenges, combined with N. fowleri's growing epidemiological footprint driven by climate change and the recent emergence of high-mortality outbreaks across South Asia, make a comprehensive, current academic review both scientifically essential and clinically timely.

Medical Journal IMJ Health Call for Papers

Conclusion
  1. World Health Organization. (2011). Naegleria fowleri. In WHO technical notes on drinking-water, sanitation and hygiene in emergencies. WHO.
  2. Yoder, J. S., Straif-Bourgeois, S., Roy, S. L., Moore, T. A., Visvesvara, G. S., Ratard, R. C., & Hill, V. R. (2012). Primary amebic meningoencephalitis deaths associated with sinus irrigation using contaminated tap water. Clinical Infectious Diseases, *55*(9), e79–e85. https://doi.org/10.1093/cid/cis626
  3. Visvesvara, G. S., Moura, H., & Schuster, F. L. (2007). Pathogenic and opportunistic free-living amoebae: Acanthamoeba spp., Balamuthia mandrillaris, Naegleria fowleri, and Sappinia diploidea. FEMS Immunology & Medical Microbiology, *50*(1), 1–26. https://doi.org/10.1111/j.1574-695X.2007.00232.x
  4. Cope, J. R., & Ali, I. K. (2016). Primary amebic meningoencephalitis: What have we learned in the last 5 years? Current Infectious Disease Reports, *18*(10), Article 31. https://doi.org/10.1007/s11908-016-0545-8
  5. Capewell, L. G., Harris, A. M., Yoder, J. S., Cope, J. R., Eddy, B. A., Roy, S. L., Visvesvara, G. S., Fox, L. M., & Beach, M. J. (2015). Diagnosis, clinical course, and treatment of primary amoebic meningoencephalitis in the United States, 1937–2013. Journal of the Pediatric Infectious Diseases Society, *4*(4), e68–e75. https://doi.org/10.1093/jpids/piu103
  6. Centers for Disease Control and Prevention. (2024). Naegleria fowleri — Primary amebic meningoencephalitis (PAM). https://www.cdc.gov/parasites/naegleria/
  7. Siddiqui, R., & Khan, N. A. (2014). Primary amoebic meningoencephalitis caused by Naegleria fowleri: An old enemy presenting new challenges. PLOS Neglected Tropical Diseases, *8*(8), Article e3017. https://doi.org/10.1371/journal.pntd.0003017
  8. Siddiqui, R., Maciver, S. K., & Khan, N. A. (2025). Naegleria fowleri: Emerging therapies and translational challenges. Expert Review of Anti-Infective Therapy, *23*(9), 753–761. https://doi.org/10.1080/14787210.2025.2498312
  9. Fowler, M., & Carter, R. F. (1965). Acute pyogenic meningitis probably due to Acanthamoeba sp.: A preliminary report. British Medical Journal, *2*(5464), 740–742. https://doi.org/10.1136/bmj.2.5464.740
  10. Visvesvara, G. S. (1991). Free-living amebae as opportunistic agents of human disease. Journal of Neuropathology and Experimental Neurology, *50*(3), 195–211. https://doi.org/10.1097/00005072-199105000-00001
  11. Carter, R. F. (1972). Primary amoebic meningoencephalitis: An appraisal of present knowledge. Transactions of the Royal Society of Tropical Medicine and Hygiene, *66*(2), 193–213. https://doi.org/10.1016/0035-9203(72)90143-0
  12. De Jonckheere, J. F. (2011). What do we know by now about the ecology and biology of the pathogenic free-living amoeba Naegleria fowleri? Experimental Parasitology, *128*(1), 19–22. https://doi.org/10.1016/j.exppara.2011.01.009
  13. Linam, W. M., Ahmed, M., Cope, J. R., Chu, C., Visvesvara, G. S., da Silva, A. J., Qvarnstrom, Y., & Green, J. (2015). Successful treatment of an adolescent with Naegleria fowleri primary amebic meningoencephalitis. Pediatrics, *135*(3), e744–e748. https://doi.org/10.1542/peds.2014-2292
  14. Cope, J. R., Conrad, D. A., Cohen, N., Cotter, M., da Silva, A., Jackson, J., & Visvesvara, G. S. (2016). Use of the novel therapeutic agent miltefosine for the treatment of primary amebic meningoencephalitis. Clinical Infectious Diseases, *62*(6), 774–776. https://doi.org/10.1093/cid/civ1029
  15. Kemble, S. K., Lynfield, R., DeVries, A. S., Drehner, D. M., Pomputius, W. F., Beach, M. J., Visvesvara, G. S., & Smith, K. E. (2012). Fatal Naegleria fowleri infection acquired in Minnesota: Possible expanding range of a deadly thermophilic organism. Clinical Infectious Diseases, *54*(6), 805–809. https://doi.org/10.1093/cid/cir961
  16. Marciano-Cabral, F., MacLean, R., Mensah, A., & LaPat-Polasky, L. (2003). Identification of Naegleria fowleri in recreational waters and sediment of the United States Gulf Coast. Journal of Eukaryotic Microbiology, *50*(Suppl.), 715–716. https://doi.org/10.1111/j.1550-7408.2003.tb00671.x
  17. Government of Kerala, Department of Health and Family Welfare. (2024). Technical guidelines on prevention, diagnosis and management of amoebic meningoencephalitis (G.O. Rt. No. 1760/2024/H&FWD).
  18. Indian Council of Medical Research. (2024). ICMR guidelines for diagnosis and management of Naegleria fowleri infections.
  19. Culbertson, C. G. (1971). The pathogenicity of soil amoebas. Annual Review of Microbiology, *25*, 231–254. https://doi.org/10.1146/annurev.mi.25.100171.001311
  20. Schuster, F. L., & Visvesvara, G. S. (2004). Free-living amoebae as opportunistic and non-opportunistic pathogens of humans and animals. International Journal for Parasitology, *34*(9), 1001–1027. https://doi.org/10.1016/j.ijpara.2004.06.004
  21. Yoder, J. S., Eddy, B. A., Visvesvara, G. S., Capewell, L., & Beach, M. J. (2010). The epidemiology of primary amoebic meningoencephalitis in the USA, 1962–2008. Epidemiology and Infection, *138*(7), 968–975. https://doi.org/10.1017/S0950268809991014
  22. Fritz-Laylin, L. K., Prochnik, S. E., Ginger, M. L., Dacks, J. B., Carpenter, M. L., Field, M. C., Kuo, A., Paredez, A., Chapman, J., Pham, J., Shu, S., Neupane, R., Cipriano, M., Mancuso, J., Tu, H., Salamov, A., Lindquist, E., Shapiro, H., Lucas, S., ... Dawson, S. C. (2010). The genome of Naegleria gruberi illuminates early eukaryotic versatility. Cell, *140*(5), 631–642. https://doi.org/10.1016/j.cell.2010.01.032
  23. Debnath, A., Tunac, J. B., Silva-Olivares, A., Galindo-Gómez, S., Shibayama, M., & McKerrow, J. H. (2012). In vitro efficacy of auranofin alone and in combination against Naegleria fowleri. Antimicrobial Agents and Chemotherapy, *56*(5), 2861–2863. https://doi.org/10.1128/AAC.06430-11
  24. Bhatt, K., Bhatt, D. K., & Bhatt, U. K. (2021). Emerging drug candidates for primary amoebic meningoencephalitis: A review. Journal of Parasitology Research, *2021*, Article 6698752. https://doi.org/10.1155/2021/6698752
  25. Lainhart, W., & Cerva, L. (2013). Identification of environmental Naegleria fowleri by real-time PCR in the southeastern United States. Applied and Environmental Microbiology, *79*(10), 3350–3354. https://doi.org/10.1128/AEM.00252-13
  26. De Jonckheere, J. F. (2002). A century of research on the amoeboflagellate genus Naegleria. Acta Protozoologica, *41*, 309–342.
  27. Khan, N. A. (2006). Naegleria fowleri: Biology and pathogenesis. Microbes and Infection, *8*(1), 167–173. https://doi.org/10.1016/j.micinf.2005.06.024
  28. Siddiqui, R., Saleem, S., & Khan, N. A. (2012). Virulence factors of Naegleria fowleri and pathogenesis of PAM. Expert Review of Anti-Infective Therapy, *10*(7), 765–769. https://doi.org/10.1586/eri.12.62
  29. John, D. T. (1982). Primary amebic meningoencephalitis and the biology of Naegleria fowleri. Annual Review of Microbiology, *36*, 101–123. https://doi.org/10.1146/annurev.mi.36.100182.000533
  30. Rohr, U., Weber, S., Michel, R., Selenka, F., & Wilhelm, M. (1998). Comparison of free-living amoebae in hot water systems of hospitals. Applied and Environmental Microbiology, *64*(5), 1822–1824. https://doi.org/10.1128/AEM.64.5.1822-1824.1998
  31. De Jonckheere, J. F., Brown, S., Robinson, B. S., & Dobson, P. J. (1988). Identification of Naegleria species by restriction endonuclease digestion of whole-cell DNA. Transactions of the Royal Society of Tropical Medicine and Hygiene, *82*(2), 224–227. https://doi.org/10.1016/0035-9203(88)90415-2
  32. Marciano-Cabral, F. (2004). The immune response to Naegleria fowleri amebae and pathogenesis of infection. FEMS Immunology & Medical Microbiology, *40*(1), 25–36. https://doi.org/10.1016/S0928-8244(03)00280-1
  33. Siddiqui, R., Bhatt, K., Ahmed, K., & Khan, N. A. (2016). Olfactory neuroepithelium: The main portal of entry for Naegleria fowleri. Annals of Clinical Microbiology and Antimicrobials, *15*(1), Article 42. https://doi.org/10.1186/s12941-016-0155-6
  34. Siddiqui, R., Ali, I. K., Cope, J. R., & Khan, N. A. (2016). Biology and pathogenesis of Naegleria fowleri. Acta Tropica, *164*, 375–394. https://doi.org/10.1016/j.actatropica.2016.09.022
  35. Ahmad, A. F., Cope, J. R., & Ali, I. K. (2015). Recent advances in the pathogenesis of Naegleria fowleri and possibilities of new drug targets. Journal of Eukaryotic Microbiology, *62*(4), 523–531. https://doi.org/10.1111/jeu.12218
  36. Deetz, T. R., Sawyer, M. H., Billman, G., Schuster, F. L., & Visvesvara, G. S. (2003). Successful treatment of Naegleria fowleri meningoencephalitis: Clinical review. Clinical Infectious Diseases, *36*(10), 1267–1272. https://doi.org/10.1086/374838
  37. Schuster, F. L., & Visvesvara, G. S. (2004). Opportunistic amoebae: Challenges in prophylaxis and treatment. Drug Resistance Updates, *7*(1), 41–51. https://doi.org/10.1016/j.drup.2004.01.002
  38. Siddiqui, R., Bhatt, K., Bhatt, D. K., & Khan, N. A. (2020). Towards identification of potential drug targets in Naegleria fowleri. ACS Infectious Diseases, *6*(2), 121–132. https://doi.org/10.1021/acsinfecdis.9b00367
  39. Kolar, S. S., Mehta, R. T., Bhatt, D. K., & Bhatt, K. (2021). Nanoparticle-mediated drug delivery strategies for amebic infections. Expert Opinion on Drug Delivery, *18*(7), 923–934. https://doi.org/10.1080/17425247.2021.1867103
  40. Borkens, Y. (2024). The pathology of the brain eating amoeba Naegleria fowleri. Indian Journal of Microbiology, *64*(3), 1384–1394. https://doi.org/10.1007/s12088-024-01264-1
  41. Ali, S., Al-Islam, K. M. N., Murad, M. W., & Tithi, T. (2025). A comprehensive narrative review of Naegleria fowleri infections: Emerging epidemiology, molecular pathogenesis and therapeutic advances (2020–2025). Asian Journal of Research in Medical and Pharmaceutical Sciences, *14*, 143–163.
  42. Dai, L., Guo, X. R., Chen, X. R., Wang, Y., & Liu, H. (2025). A review of the mechanism, diagnosis, and treatment of Naegleria fowleri infection. Frontiers in Microbiology, *16*, Article 1686695. https://doi.org/10.3389/fmicb.2025.1686695
  43. Butt, C. G. (1966). Primary amebic meningoencephalitis. New England Journal of Medicine, *274*(26), 1473–1476. https://doi.org/10.1056/NEJM196606302742605
  44. Carter, R. F. (1970). Description of Naegleria sp. isolated from two cases of primary amoebic meningoencephalitis. The Journal of Pathology, *100*(4), 217–244. https://doi.org/10.1002/path.1711000403
  45. World Health Organization. (2003). Guidelines for safe recreational water environments: Vol. 1. Coastal and fresh waters.
  46. Pond, K. (2005). Water recreation and disease: Plausibility of associated infections. IWA Publishing.
  47. Martinez, A. J., & Visvesvara, G. S. (1997). Free-living, amphizoic and opportunistic amebas. Brain Pathology, *7*(1), 583–598. https://doi.org/10.1111/j.1750-3639.1997.tb01082.x
  48. Kim, J. H., Jung, S. Y., Lee, Y. J., & Park, S. J. (2015). Effect of therapeutic hypothermia on the course of primary amebic meningoencephalitis. Neurology, *84*(2), 210–211. https://doi.org/10.1212/WNL.0000000000001125
  49. Vargas-Zepeda, J., Gomez-Alcala, A. V., Vasquez-Morales, J. A., Licea-Amaya, L., De Jonckheere, J. F., & Lares-Villa, F. (2005). Successful treatment of Naegleria fowleri meningoencephalitis using intravenous amphotericin B, fluconazole and rifampicin. Archives of Medical Research, *36*(1), 83–86. https://doi.org/10.1016/j.arcmed.2004.11.003
  50. Centers for Disease Control and Prevention. (2024). Naegleria fowleri: Resources for health professionals. https://www.cdc.gov/parasites/naegleria/health-professionals.html 
References

Naegleria fowleri exemplifies a biological paradox that challenges modern medicine: a microscopically small, environmentally ubiquitous organism capable of defeating the immunological and pharmacological arsenal of the 21st century with near-perfect consistency. Six decades of sustained scientific investigation have illuminated its biology, ecology, pathogenesis, and therapeutic vulnerabilities in remarkable detail, yet the case fatality rate remains obstinately above 97%, and the global case burden is growing rather than declining.

This review has synthesised current knowledge across all dimensions of N. fowleri science: its phylogenetically ancient taxonomy within Percolozoa; the morphological elegance of its three developmental forms; the thermophilic ecology that makes rising global temperatures an increasingly powerful epidemiological driver; its expanding geographic distribution documented by cases in previously non-endemic northern US states and by the unprecedented 2024–2025 Kerala outbreak; the molecular choreography of its nasal-to-brain invasion pathway; and its sophisticated virulence arsenal — naegleriapores, Nfa1-mediated trogocytosis, cathepsin B-driven immune evasion, and GPCR-mediated neurotropic chemotaxis.

On the diagnostic and therapeutic fronts, real-time PCR has transformed detection speed and sensitivity, miltefosine has introduced the first genuinely new pharmacological class into PAM management in decades, and combination regimen optimisation has produced a small but statistically significant cohort of survivors. Yet fundamental barriers remain: a diagnostic window compressed to hours by explosive disease progression; BBB pharmacokinetics that prevent reliable CNS drug delivery; an absence of validated treatment response biomarkers; and global inequity in access to miltefosine and molecular diagnostics.

Two overarching messages emerge from this review. First, PAM is a preventable disease — the singular, well-defined transmission route means that informed public behaviour, rigorous water quality management, and accessible safe-water technologies can prevent virtually all cases. The gap between this preventability and the ongoing case toll is a remediable failure of public awareness, clinical education, and institutional infrastructure. Second, N. fowleri is an organism whose epidemiological trajectory is unfavourable in a warming world. The investment required to close the diagnostic, therapeutic, and preventive gaps — in research funding, regulatory facilitation, international data sharing, and health system capacity building — is modest relative to the human tragedy of every preventable PAM death. The scientific and public health communities must act with the urgency that a 97% fatality rate demands.

Article Preview
Quick Actions
Download PDF View References
Article Info
Pages
04-18